FDA Approves First Dual-Vector Gene Therapy For OTOF-Related Congenital Deafness
The U.S. Food and Drug Administration this week approved Otarmeni (lunsotogene parvec-cwha), the first dual-AAV gene therapy for severe to profound congenital hearing loss caused by OTOF gene mutations.
The approval covers pediatric and adult patients with OTOF-related hearing loss who have preserved outer hair cell function and no prior cochlear implant in the treated ear. The one-time treatment is delivered bilaterally to the inner ear via needle and microcatheter. Common side effects reported include middle ear infection, nausea, dizziness and procedural pain. The FDA called the therapy "groundbreaking" and approved it under the National Priority Voucher pilot program.
The path to approval traces back to 1999, when OTOF mutations were identified as a cause of nonsyndromic congenital deafness by disrupting otoferlin and synaptic transmission in inner ear hair cells. Decibel Therapeutics formed in 2015 and partnered with Regeneron in 2017 to develop a dual-AAV product, DB-OTO; Regeneron later acquired Decibel and moved the program through manufacturing and clinical testing. The phase 1/2 CHORD trial began in September 2023; early pediatric results in 2024 showed significant hearing gains, and 2025 data supported safety and efficacy in broader groups.
About 200,000 people worldwide are deaf because of OTOF mutations, and roughly 2 to 3 per 1,000 U.S. children are born with detectable hearing loss, so the therapy targets a defined but meaningful patient group. Social media hailed the approval as a breakthrough, with some posts noting trial reports that about 80% of treated patients reached natural hearing thresholds and many regained whisper-level hearing. Regeneron says it will provide Otarmeni at no cost to eligible U.S. patients, and the FDA will hold a public meeting on June 4 to discuss rollout, eligibility and distribution.
📊 Relevant Data
Approximately 200,000 people worldwide are deaf due to mutations in the OTOF gene.
Experimental Gene Therapy Enables Hearing in Five Children Born Deaf — Harvard Medical School
In the United States, about 2 to 3 out of every 1,000 children are born with a detectable level of hearing loss in one or both ears.
Quick Statistics About Hearing, Balance, & Dizziness — National Institute on Deafness and Other Communication Disorders (NIDCD)
The manufacturer, Regeneron, is providing the gene therapy Otarmeni at no cost to eligible patients in the United States.
FDA approves first gene therapy for genetic hearing loss — NBC News
📌 Key Facts
- The FDA approved Otarmeni (lunsotogene parvec-cwha), the first dual adeno-associated virus (AAV) vector–based gene therapy for hearing loss.
- The therapy is indicated for pediatric and adult patients with severe to profound hearing loss linked to the OTOF gene, provided outer hair cell function is preserved and the treated ear has not previously received a cochlear implant.
- Otarmeni is delivered as a one-time, bilateral inner-ear (cochlear) surgical procedure using a needle and microcatheter.
- Common side effects reported include middle ear infection, nausea, dizziness, and procedural pain.
- The FDA described the approval as "groundbreaking" and designated the product as the sixth drug—and the first gene therapy—approved under the National Priority Voucher (CNPV) pilot program.
- The FDA will hold a public meeting on June 4 to discuss program implementation, eligibility criteria, and distribution processes for the therapy.
📰 Source Timeline (2)
Follow how coverage of this story developed over time
- Identifies the approved product as Otarmeni (lunsotogene parvec-cwha), the first dual adeno-associated virus vector-based gene therapy.
- Notes FDA characterization of the therapy as "groundbreaking" and that it is the sixth drug and first gene therapy approved under the National Priority Voucher (CNPV) pilot program.
- Clarifies indication: treatment for pediatric and adult patients with severe to profound hearing loss linked to the OTOF gene, with preserved outer hair cell function and no prior cochlear implant in the treated ear.
- Details administration: a one-time, bilateral inner-ear (cochlear) surgical delivery via needle and microcatheter.
- Lists common side effects including middle ear infection, nausea, dizziness, and procedural pain.
- Reports that the FDA will hold a public meeting on June 4 to discuss program implementation, eligibility criteria, and distribution processes for the therapy.